Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors
Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer
Gleevec Approval Sets Record For FDA Review: 73 Days
Advances Found In Treatment Of Aerodigestive Cancers
Silicone Implants Not Linked To Increased Risk Of Death
B-14 Trial: No Advantage To 10 Years Of Tamoxifen
NCI-Approved Clinical Trials Listed For April 2001
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









